Julia Krämer1, Felix Glaser1, Martin Hasselblatt2, Eva Brand3, Christian Pogoda4, Malte Lenders3, Heinz Wiendl1, Sven G Meuth1,5, Thomas Duning1. 1. Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. 2. Institute of Neuropathology, University Hospital Münster, Münster, Germany. 3. Department of Internal Medicine D and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany. 4. Department of Cardiology I-Coronary and Peripheral Vascular Disease and Heart Failure and Interdisciplinary Fabry Center (IFAZ), University Hospital Münster, Münster, Germany. 5. Department of Neurology, University Hospital Düsseldorf, Düsseldorf, Germany.
Abstract
Background: While cerebral lesions are common in Fabry disease (FD), spinal lesions have not been described, and their presence was suggested to be indicative of multiple sclerosis. Here, we present a FD patient with histopathological confirmed spinal ischemic stroke. Case presentation: A patient with genetically and biochemically diagnosed FD and characteristic manifestations (acroparesthesia, angiokeratomas, hypohidrosis, microalbuminuria, myocardial hypertrophy) presented with paraplegia, loss of all sensory modalities below Th9, and loss of bowel and bladder function. While cranial MRI was inconspicuous, spinal MRI showed a T2 hyperintense, non-contrast-enhancing lesion of the thoracic spinal cord. Lumbar puncture revealed mild pleocytosis, increased total protein and lactate levels, decreased glucose ratio, and negative oligoclonal bands. Rheumatic, neoplastic, and infectious disorders were excluded. The patient received intravenous and intrathecal methylprednisolone, plasmapheresis, intravenous immunoglobulins, and cyclophosphamide without clinical improvement. A biopsy of the thoracic lesion was performed. A histopathological examination revealed necrotic tissue consistent with spinal cord ischemia. Diagnostic work-up for stroke etiology clarification was not conspicuous. Two years onward, the patient suffered from a pontine infarction and a transient ischemic attack. Conclusion: The current case highlights the possible occurrence of spinal ischemic lesions in FD. Thus, the diagnosis of FD should not be prematurely discarded in the presence of spinal lesions.
Background: While cerebral lesions are common in Fabry disease (FD), spinal lesions have not been described, and their presence was suggested to be indicative of multiple sclerosis. Here, we present a FDpatient with histopathological confirmed spinal ischemic stroke. Case presentation: A patient with genetically and biochemically diagnosed FD and characteristic manifestations (acroparesthesia, angiokeratomas, hypohidrosis, microalbuminuria, myocardial hypertrophy) presented with paraplegia, loss of all sensory modalities below Th9, and loss of bowel and bladder function. While cranial MRI was inconspicuous, spinal MRI showed a T2 hyperintense, non-contrast-enhancing lesion of the thoracic spinal cord. Lumbar puncture revealed mild pleocytosis, increased total protein and lactate levels, decreased glucose ratio, and negative oligoclonal bands. Rheumatic, neoplastic, and infectious disorders were excluded. The patient received intravenous and intrathecal methylprednisolone, plasmapheresis, intravenous immunoglobulins, and cyclophosphamide without clinical improvement. A biopsy of the thoracic lesion was performed. A histopathological examination revealed necrotic tissue consistent with spinal cord ischemia. Diagnostic work-up for stroke etiology clarification was not conspicuous. Two years onward, the patient suffered from a pontine infarction and a transient ischemic attack. Conclusion: The current case highlights the possible occurrence of spinal ischemic lesions in FD. Thus, the diagnosis of FD should not be prematurely discarded in the presence of spinal lesions.
Authors: Natalia S Rost; Lisa Cloonan; Allison S Kanakis; Kaitlin M Fitzpatrick; Danielle R Azzariti; Virginia Clarke; Charles M Lourenco; Dominique P Germain; Juan M Politei; György A Homola; Claudia Sommer; Nurcan Üçeyler; Katherine B Sims Journal: Neurology Date: 2016-04-20 Impact factor: 9.910
Authors: A Fellgiebel; I Keller; D Marin; M J Müller; I Schermuly; I Yakushev; J Albrecht; H Bellhäuser; M Kinateder; M Beck; P Stoeter Journal: Neurology Date: 2009-01-06 Impact factor: 9.910
Authors: Olivier Lidove; Michael L West; Guillem Pintos-Morell; Ricardo Reisin; Kathy Nicholls; Luis E Figuera; Rossella Parini; Luiz R Carvalho; Christoph Kampmann; Gregory M Pastores; Atul Mehta Journal: Genet Med Date: 2010-11 Impact factor: 8.822
Authors: C M Eng; J Fletcher; W R Wilcox; S Waldek; C R Scott; D O Sillence; F Breunig; J Charrow; D P Germain; K Nicholls; M Banikazemi Journal: J Inherit Metab Dis Date: 2007-03-08 Impact factor: 4.750
Authors: Tobias Böttcher; Arndt Rolfs; Christian Tanislav; Andreas Bitsch; Wolfgang Köhler; Jens Gaedeke; Anne-Katrin Giese; Edwin H Kolodny; Thomas Duning Journal: PLoS One Date: 2013-08-28 Impact factor: 3.240